XML 50 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Details Narrative)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 31, 2019
USD ($)
$ / shares
shares
Jan. 31, 2019
USD ($)
$ / shares
Jul. 31, 2018
USD ($)
May 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
Segment
$ / shares
shares
Mar. 31, 2018
USD ($)
shares
Jan. 02, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
$ / shares
Loss from operations         $ (556) $ (1,781)      
Accumulated deficit $ (62,853)       (62,853)     $ (74,211)  
Net cash used in operating activities         (1,476) $ (965)      
Cash resources and restricted investments, marketable securities 4,265       $ 4,265        
Number of segments | Segment         2        
Non controlling interest description         Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest        
Antidilutive securities | shares         5,838,230 10,106,391      
Right of use asset 6,195       $ 6,195   $ 6,325  
Lease liability $ 6,594       $ 6,594   $ 6,712  
Melt Series A Stock [Member]                  
Stock price per shares | $ / shares $ 5.00 $ 5.00     $ 5.00        
Proceeds from issuance of preferred stock $ 11,400 $ 11,400              
Surface Series A Stock [Member]                  
Proceeds from issuance of preferred stock     $ 21,000 $ 21,000          
Eton Pharmaceuticals, Inc. [Member]                  
Number of shares owned | shares 3,500,000       3,500,000        
Stock price per shares | $ / shares $ 8.00       $ 8.00        
Ownership percentage 19.86%       19.86%        
Gain on investment         $ 6,580        
Fair market value of investments $ 28,000       $ 28,000        
Melt Pharmaceuticals, Inc. [Member]                  
Number of shares owned | shares 3,500,000       3,500,000        
Ownership percentage 44.00%       44.00%        
Gain on deconsolidation amount         $ 5,810        
Net income (loss)         285        
Carrying value of investments $ 5,525       5,525        
Surface Pharmaceuticals Inc [Member]                  
Loss from operations         $ 812        
Number of shares owned | shares 3,500,000       3,500,000        
Stock price per shares | $ / shares                 $ 3.30
Ownership percentage 30.00%       30.00%        
Gain on deconsolidation amount         $ 5,320        
Net income (loss)         243        
Carrying value of investments $ 4,704       $ 4,704        
Restricted Stock Units [Member]                  
Number of shares vested during the period | shares         270,783 152,790